Documente Academic
Documente Profesional
Documente Cultură
Redactor ef:
Dan PRELIPCEANU
Redactor-efi
adjunci:
Drago MARINESCU
Aurel NIRETEAN
COLECTIV REDACIONAL
Doina COZMAN
Liana DEHELEAN
Marieta GABO GRECU
Maria LADEA
Cristinel TEFNESCU
Ctlina TUDOSE
Secretari de redacie: Elena CLINESCU
Valentin MATEI
CONSILIU TIINIFIC
Vasile CHIRI (membru de onoare
al Academiei de tiine Medicale,
Iai)
Michael DAVIDSON (Professor, Sackler
School of Medicine Tel Aviv Univ.,
Mount Sinai School of Medicine,
New York)
Virgil ENTESCU (membru al Academiei de
tiine Medicale, Satu Mare)
Ioana MICLUIA (UMF Cluj-Napoca)
erban IONESCU (Universitatea
Paris VIII, Universitatea TroisRivieres, Quebec)
Mircea LZRESCU (membru de onoare al
Academiei de tiine Medicale,
Timisoara)
Juan E. MEZZICH (Professor of Psychiatry
and Director, Division of Psychiatric
Epidemiology and International
Center for Mental Health, Mount
Sinai School of Medicine, New York
University)
Teodor T. POSTOLACHE, MD (Director,
Mood and Anxiety Program,
Department of Psychiatry,
University of Maryland School of
Medicine, Baltimore)
Sorin RIGA (cercettor principal gr.I)
Dan RUJESCU (Head of Psychiatric
Genomics and Neurobiology
and of Division of Molecular and
Clinical Neurobiology, Department
of Psychiatry, Ludwig- MaximiliansUniversity, Munchen)
Eliot SOREL (George Washington
University, Washington DC)
Maria GRIGOROIU-ERBNESCU
(cercettor principal gr.I)
Tudor UDRITOIU (UMF Craiova)
ARPP
ASOCIAIA ROMN
DE PSIHIATRIE I PSIHOTERAPIE
www.romjpsychiat.ro
REVISTA
ROMN
de
PSIHIATRIE
Nr. 2
June 2016
QUARTERLY
CNCSIS B+
p-ISSN: 1454-7848
e-ISSN: 2068-7176
CUPRINS
ARTICOLE SPECIALE
& Depresia i suicidul la personajele feminine ale literaturii secolului XX
29
ARTICOLE DE SINTEZ
& Persoana delirant ca actor ntr-un scenariu aberant
34
ARTICOLE ORIGINALE
& Delirul mistic i perspectiva realitilor multiple
39
45
& Depresia la tinerii aduli cu afeciuni somatice cronice - o analiz efectuat pe cohorta 1970 din
Marea Britanie
51
CAZ CLINIC
& Psihoza rezistent la un pacient cu comorbiditi - talasemie beta si toxoplasmoz latent
55
59
Mihai Ardelean
INSTRUCIUNI PENTRU AUTORI
Revista Romn de Psihiatrie este indexat de Consiliul Naional al Cercetrii tiinifice din
nvmntul Superior la categoria B+. Apare trimestrial.
Colegiul Medicilor din Romnia acord abonailor la aceast publicaie 5 credite EMC/an.
Articolele tiinifice publicate n revist sunt creditate cu 80 credite EMC/articol.
Revista Romn de Psihiatrie este editat de Asociaia Romn de Psihiatrie i Psihoterapie
i Asociaia Medical Romn
64
SPECIAL ARTICLES
29
Ionu I. Jeican, Doina C.M. Cozman: Depression and Suicide In Women Characters of The Early 20th Century
Ionu I. Jeican, Doina C.M. Cozman: Depression and Suicide In Women Characters of The Early 20th Century
***
33
REVIEW ARTICLES
INTRODUCTION
MD, PhD, Prof Dr, Eduard Pamfil Dept. Of Psychiatry, Univ. of Medicine Timisoara, I. Vacarescu Str. 21, mlazarescu_39@yahoo.com
MD, a 3rd year resident in psychiatry, Eduard Pamfil Dept. Of Psychiatry, Univ. of Medicine Timisoara, Psychiatric Clinic Timisoara.
Received October 29, 2015, Revised November 20, 2015, Accepted December 4, 2015
2
34
Mircea Lzrescu, Marinela Hurmuz: The Deluded Person As An Actor In An Aberrant Scenario
process of education.
The subject has at his disposal the multiple
realities (MR) and he is permanently connected to them
in his everyday life. He can enter these realities if he needs
or if he wants to (Table 1).
Table 1. The main realities connected to the SCR
a)
dreams;
b)
the religious and mythic reality, when participating to
the sacral rituals of prayer or other religious practices;
c)
going to theatre plays or movies; it also includes the
reality of an actor who is performing in a play and who is
transposed into a fictional reality. A special case is the one of
the writer of a play, who is directing and then playing a role in
it;
d)
the reality of video games;
e)
the reality of different feasts, such as carnivals;
f)
reading a novel or listening to stories; this category
also includes the special case of the novel writer, who gives
life to special characters and situations;
g)
listening to or participating in everyday narrative
histories regarding known or unknown persons;
h)
the artistic creativity, for example poetry or painting,
but also the scientific, theoretic creativity;
i)
creativity in the domain of mathematics and
philosophy;
j)
the trance and mystic - ecstatic states; visions;
k)
the delusional reality.
37
Mircea Lzrescu, Marinela Hurmuz: The Deluded Person As An Actor In An Aberrant Scenario
38
REFERENCES
1.Bertolotti, L. 2010. Delusions and other irrational beliefs. Oxford:
Oxford University Press.
2.Eliade, M. 1963. Aspects du mythe. Gallimard.
3.Eliade, M. 1971. The Myth of the Eternal Return: Cosmos and History.
Princeton: Princeton University Press.
4.Eliade, M. 1987. Trait d'histoire des religions. Paris: Payot.
5.Enoch, D. 1991. Delusional jealousy and awareness of reality. British
Journal of Psychiatry, no. 159 (Suppl 14): 6-13.
6.Gallagher, S. 2009. Delusional realities. In Psychiatry as Cognitive
Neuroscience. Philosophical perspectives, ed. M. Broome, L. Bortolotti,
245-268. Oxford: Oxford University Press.
7.Hermans, H. 1996. Voicing the Self: From Information Processing to
Dialogical Interchange. Psychological Bulletin, no. 119:31-50.
7.Hollander, E. 1993. Obsessive-Compulsive Related Disorders.
Washington: American Psychiatry Press.
8.Jaspers, K. 1997. General Psychopathology. Baltimore and London:
Johns Hopkins University Press.
9.Jaspers, K. 1963. Eifersuchtswahn, ein Beitrag zur Frage: Entwicklung
oder Proze. In Gesammelte Schriften zur Psychopathologie, ed. K.
Jaspers, 85-141. Berlin: Springer Verlag. (Original work published in
1910).
10.Kretschmer, E. 1974. The sensitive delusion of reference. In Themes
and Variations in European Psychiatry: An Anthology, ed. S.R. Hirsch
and M. Shepherd, 157-166. Bristol: John Wright.
11.McAdams, D.P. 2008. Personal Narratives and the Life Story. In
Handbook of Personality. Theory and Research, ed. O.P. John, R.W.
Robins, L.A. Pervin, 242-264. New York, London: Guilford Press.
12.Minkovski, E. 1927. La schizophrnie: Psychopathologie des
schizodes et des schizophrnes. Paris: Payot.
13.Oyebode, F. 2008. Sims' symptoms in the mind: An Introduction to
Descriptive Psychopathology, 4th ed. Edinburgh, London: Sauders
Elsevier.
14.Parnas, J., and Sass, L.A. 2011. The structure of self-consciousness
and the problem of self. In The Oxford Textbook of the Self, ed. S.
Gallagher, 521-546. Oxford: Oxford University Press.
15.Shepherd, M. 1990. Morbid jealousy: some clinical and social aspects
of a psychiatric symptom. In Conceptual Issues in Psychological
Medicine, ed. M. Shepherd, 39-68. London and New York: Routledge.
16.Stanghellini, G. 2000. Disembodied Spirits and Deanimated Bodies:
The Psychopathology of Common Sense. Oxford: Oxford University
Press.
17.Stephens, G.,L., and G. Graham. 2009. The delusional stance. In
Psychiatry as Cognitive Neuroscience. Philosophical perspectives, ed.
M. Broome and L. Bortolotti, 193-216. Oxford: Oxford University Press.
Tulving, E. 1983. Elements of Episodic Memory. Oxford: Clarendon
Press.
18.World Health Organisation 1992. The ICD-10 Classification of
Mental and Behavioural Disorders: Clinical Descriptions and
Diagnostic Guidelines. Geneva: World Health Organisation.
***
ORIGINAL ARTICLES
Senior Psychiatrist, MD, PhD, University Professor, Department of Psychiatry, Victor Babes University of Medicine and Pharmacy, Eduard Pamfil
Psychiatric University Clinic, 21 I. Vacarescu, Timisoara, 300128, Romania. Correspondence e-mail: mlazarescu39@yahoo.com
2
Statistician, Eduard Pamfil Psychiatric University Clinic, 21 I. Vacarescu, Timisoara, 300128, Romania.
3
Resident in Psychiatry, MD, Eduard Pamfil Psychiatric University Clinic, 21 I. Vacarescu, Timisoara, 300128, Romania.
Received January 14, 2016, Revised January 15, 2016, Accepted January 18, 2016
39
Mircea Lzrescu, Jenica Blajovan, Marinela Hurmuz: The Religious Delusion And The multiple Realities
Perspective
mentioned in the manuals of diagnosis and it is less studied
than the other types of delusions (11,12, 13). Sims (14)
discussed the religious delusion from a
psychopathological point of view. This theme has been
less common during the 20th century in western
civilization (15). The religious delusion can be found in
most of the psychotic disorders, especially in
schizophrenia (16,17,18,19,20,21), delusional persistent
disorder and bipolar disorder. It is more frequently
expressed through a special mission given to the patient by
God for fighting the evil or saving the world. It is
sometimes accompanied by his identification with one of
the divine figures. The presence of the devil can be
experienced as body possession or through thought and
behaviour influence (22).
A special feature of the religious delusion is the
fact that it refers to a supernatural reality which is
organized in a mythical, narrative way and it is
traditionally, socially and culturally admitted as a special
reality. The sacral figure is accepted by official
institutions and current community practices. The sacral
universe is an undoubted reality for the normal believer,
which is parallel with the physical and social everyday
reality. It is a far away, transcendent reality. The access to
this reality is possible through individual and collective
prayers. The characters of this world are omnipotent in
relation to humans and they have access to one's intimate
life.
In Christianity, the main characters are God,
Jesus Christ, the Holy Spirit, Virgin Mary, who have
family-like relationships. In addition, there is the Devil.
The main event is the Death and Resurrection of Jesus.
The most important themes are: fighting against the devil,
saving humankind, the End of the World. God takes care
of man, he protects him and can send him special
messages and missions. The religious delusion is, by
definition, a relational one, expressing the subject's
relation to the supernatural, omnipotent characters. The
profane relational delusion in the paranoid disorder refers
to hostility, surveillance, cheating etc., exceptions being
only the erotomanic delusion and the undefined
descendancy. As a whole, the social relationships develop
on an intimate-public diagram. In regard to the sacral,
mythical characters, they are, by definition, in a faraway
place and they can only be approached indirectly. In
delusion, they get closer to the subject and they can
directly act upon him.
The sacral mythical scenario, the multiple
realities (MR) theme and delusion.
The multiple realities hypothesis refers, in Gallagher's
description, to the cultural narrative universe of the
theatre, literature, novels, virtual reality. The mythical
reality is not mentioned.
The characters of the narrative worlds theatre,
literature, history, biography are placed in an
intermediate position in relation to the physical social
reality of the everyday life. Generally, they are part of the
profane reality and they are not characterized by
omnipotence, like the characters of the sacral world. In
these multiple cultural worlds, we can identify some
areas that are closer to the supernatural reality (e.g.
witches, aliens) and other closer to the common existence
(historical characters, biographical heroes). The sacral
40
Mircea Lzrescu, Jenica Blajovan, Marinela Hurmuz: The Religious Delusion And The multiple Realities
Perspective
The relationship with divinity is not necessarily one of
subordination, mission or identification; the main aspect
is that the patient is part of the same world as God. He has
the same position, he is his equal. In most cases, the
identitary scenario is explicitly expressed.
Case 8. A 35-year-old woman presents paranoid
delusional episodes (2001,2002)- delusions of
persecution, poisoning, but also religious delusion: she
feels a power descending upon her while she is praying.
At the second admission in the hospital, she says: Jesus
lives through me, I am Virgin Mary and she calls her
husband Joseph or Avram.
Case 9. A 54-year-old woman develops a grandiosity
religious delusion, declaring I am God, in the same time
with a paranoid delusion: she believes that she is followed
by the police and security services, that her grandmother
was substituted with a spy and she reports her to the police.
She believes that the president and the head of the church
are her children.
The identitary aspect does not only refer to the patient's
person, but also to the substitution of her grandmother.
The delusion develops as a narrative scenario which
includes real, important characters, who become her
children.
Case 10. A 19-year-old man has a psychotic episode with
religious grandiosity: he is an important person, because
the Holy Spirit has descended upon him, he will save the
country form a disaster, people watch him in a particular
way because of his importance. In the city, there is a
witch who surveys him and knows his thoughts,
everybody can read his thoughts through the radio and
TV, he can influence the Romanian football team by
only pronouncing the word attacker. The devils' army
has 999 million members, and if we turn the number
upside down, it becomes 666-the devil's number. He does
not get out of the house because in the kingdom there is
only modern science, there are no flowers or trees. As a
child, an army of devils wanted to harm him, they pushed
him in the devil thesaurus, he hurt his head and he has been
feeling bad ever since. The devil controls his thoughts;
the whole town, the whole country knows his thoughts.
He is an important person, an Emperor or a Commander;
his mother got pregnant with the Emperor, in the same way
as Virgin Mary had and this is the way he was born. The
Emperor will send a ship to take him home...or to the
Kingdom or to Heaven, he does not know exactly
where... he fought the devils and he won...he became
free.
The religious and grandiosity delusions develop in a
narrative form, with fairytale elements. His father is an
emperor and he was born in the same way Jesus was born.
The transposing of one's identity in the fictional
narrativity constructs a narrative character who detaches
form the bodily self in the present person.
Case 11. A 33-year-old man develops grandiosity
religious ideas, having a bizarre behaviour. He is sure that
he has a new identity, inspired by the historical literature.
He is the good soul of Napoleon, whose uniform he will
wear, and he will speak on his behalf. His soul has more
covers, he is a genius, he is the people's man, a saint, his
mission is to unify the catholic and orthodox churches, so
that the people will pray to the East... He refuses to eat
and he forces his family to do the same in order to purify
themselves and become superior beings... He is
42
(23).
The religious delusion gives us an important
suggestion regarding the trans-personalization process in
the psychopathology of delusion. The subject enters a role
in an aberrant fictional scenario. These aspects can lead to
important analyses in the psychopathology of delusion,
especially because, at this level, we can discuss the
differences and correlations between faith and belief.
CONCLUSIONS
The approach of religious delusion from the
perspective of Gallagher's multiple realities suggests a
process of depersonalization/trans-personalization which
leads to the subject's identification with a role in an
aberrant scenario, in a fictional world. The fictional aspect
that characterizes the sacral universe in delusion is the
consequence of a deficit and psychic de-differentiation
induced by psychosis. If we interpret the cases of religious
delusion from this perspective, we need to pay attention to
the multiple realities fictional realities closely
connected to the everyday life, such as the reality of the
theatre, novels or virtual computer world. By describing
delusion as the fall of the subject in an aberrant role, the
existentialist-phenomenological theme of being in the
world is reviewed. This concept was approached by
Heidegger in his book Being and Time and it has
inspired the phenomenological psychopathology,
especially Binswager's approach in the field of delusion
(24). When discussing the multiple realities, Gallagher
explicitly highlights this concept. It is an idea that has
always been expressed during time by Kraus'
phenomenological-anthropological analyses (25).
Note 1
The narrative psychology of the person considers
the self as being involved in different narrations: one's
own narration about himself in various situations; but also
other's narrations of himself. The narrative self expresses
by reference to the lived episodes of different durations
and has its fundaments on the identitary structure of the
person. From Dennett's perspective, this structure is the
centre of the lived and narrated experiences. Tomkins
suggested that the person can be interpreted through the
role he plays in different scenarios which he develops for
different situational problems. Hermans discussed the
existence of several simultaneous voices of the subject.
These psycho-sociological interpretations of the person
develop an older idea of James (1890) regarding the
multiplicity of the subject's selves. This view (of a subject
playing roles in different scenarios) is in concordance with
Gallagher's perspective of multiple worlds.
Note 2
Mircea Eiade developed the idea of the
difference between the sacral and profane time. The
mythic history that forms the base of a religious belief is
considered to take place in a faraway time, in the sacral
time of the beginnings and creation. During the religious
rituals, people leave the profane time of work and
everyday preoccupations and enter the mythic time of the
origins. After that, they spend a short time of celebration,
which is also different from the profane time. The
religious ceremony can be considered the prototype of all
human celebrations. Eliade suggests that there is a third
type of time related to the time of the myth the time in
which the persons recall the historical events and stories
that funded the culture and society they live in; and the
43
Mircea Lzrescu, Jenica Blajovan, Marinela Hurmuz: The Religious Delusion And The multiple Realities
Perspective
time of the fictional narrations experienced while reading
or listening to a story or novel. This reference to the
mythic-narrative time is comprehensively connected to
the doctrine of the multiple worlds/realities.
References
1.Jaspers K. General Psychopathology. Baltimore and London: Johns
Hopkins University Press, 1997.
2.Berrios GA. The History of Mental Symptoms. Cambridge University
Press, 1996.
3.Bortolotti L. Delusions and other irrational beliefs. Oxford University
Press, 1996.
4.Ibanez-Casas I, Carvilla JA. Neuropsychology Research in Delusional
Disorder. A Comprehensive Review. Psychopathology 2012; 45(2):7895.
5.Stephens GL, Graham G. The delusional stance. In: Broome M,
Bortolotti L (eds). Psychiatry as Cognitive Neuroscience. Philosophical
perspectives. Oxford University Press, 2009, 193-216.
6.Fulford KWM. Moral Theory and Medical Practice. Cambridge:
Cambridge University Press, 1989.
7.Gallagher S. Delusional Realities. In: Broome M, Bortolotti L (eds).
Psychiatry as Cognitive Neuroscience. Philosophical perspectives.
Oxford University Press, 2009, 245-268.
8.McAdams DP. Personal Narratives and the Life Story. In: John OP,
Robins RW, Pervin LA (eds), Handbook of Personality. Theory and
Research. The Guilford Press, New York London, 2008, 242-264.
9.Eliade M. The Myth of the Eternal Return: Cosmos and History.
Princeton University Press, Princeton, 1971.
10.Eliade M. Aspects du Mythe. Gallimard, 1963.
11.World Health Organization. Schedules for Clinical Assessment in
Neuropsychiatry (SCAN). Geneva: WHO, 1992.
12.American Psychiatric Association. Diagnostic and Statistical
Manual of Mental Disorders, 4th edn, Text Revision. Washington, DC:
American Psychiatric Association, 2000.
44
***
REVIEW ARTICLES
INTRODUCTION
All chronic illnesses have the tendency to limit or even
decrease the functional status of people that live with them,
which is reflected in all life domains: psychological
(accurate understanding and interpretation of people's
behavior), social (performing a social role), occupational
(capacity to perform obligations at workplace, school and
so on), leisure (capacity to enjoy spending time doing
things that you like). Therefore the quest to achieve a better
living for people having a chronic disease, it is of
paramount importance and is in line with the current
Schizophrenia,
healthy-longevity promotion (1).
dementia and depression represent chronic and
debilitating illnesses listed by the international organisms
as top priority for public health actions to reduce disability
and improve the function and quality of life for people
living with chronic illness (2).
Schizophrenia is a heterogeneous clinical syndrome,
including positive and negative features and
neuropsychological impairment, also having impaired
social and occupational functioning as a core
characteristic.
MD, PhD; Clinical Psychiatric Hospital Prof. Dr. Al. Obregia,2nd Dept.; UMF Carol Davila,Bucharest.
MD, PhD; Clinical Psychiatric Hospital Prof. Dr. Al. Obregia,1st Dept.; UMF Carol Davila,Bucharest.
3
MD; Clinical Psychiatric Hospital Prof. Dr. Al. Obregia, 7th Dept.
4
MD; Clinical Psychiatric Hospital Prof. Dr. Al. Obregia, 2nd Dept.
Corresponding author: Valentin Matei, vm_matei@yahoo.com
Received February 1, 2016, Revised February 12, 2016, Accepted March 8, 2016
2
45
Valentin P. Matei, Alexandra Mihailescu, Traian Purnichi, Ruxandra M. Al-bataineh: Antipsychotic Treatment And
Psychosocial Functioning In Schizophrenia Results From Romanian Cohort Of Eufest Study
symptoms, as key goals for a better functioning of the
patients.
Guidelines for treatment in schizophrenia recommend
that primary treatment should be pharmacological,
antipsychotics representing the mainstay of the treatment
(6). Antipsychotics are currently classified into: first
generation, conventional or 'typical' antipsychotics
(FGAs), second generation 'atypical' antipsychotics
(SGAs) (7). Both classes of antipsychotics are targeting
positive symptoms in schizophrenia and are capable of
inducing extrapyramidal symptoms (EPS), however,
atypical antipsychotics have some evidences regarding
efficacy on negative and cognitive symptoms (8),
although the mean effect is recognized to be small (9, 10)
and are known for inducing less EPS but instead are
associated with an increased risk for metabolic syndrome
(11).
Recent studies challenge (12,13), the initial optimism that
atypical antipsychotics are indeed associated with an
improvement in negative or cognitive symptoms despite
the fact that are authors who consider that a superiority in
functionality in the case of patients treated with atypical
antipsychotics compared with patients treated with
conventional antipsychotics appear after a longer time of
treatment (14).
Future research should aim to determine the most feasible
and valid measure of functional status in schizophrenia, as
we set as a target for treatment functional recovery.
Efficacy of antipsychotics has been quantified by complex
analyses of scores in scales of symptoms reduction, like
PANSS (15, 16), but also by all-cause treatment
discontinuation - the EUFEST and CATIE studies (13,
17), and quality of life the CUtLASS study (18).
The most important goal of antipsychotic treatment in
psychotic diseases is functional recovery (19).
Assessment of functional status might represent a better
indicator of overall status of a certain schizophrenic
patient than psychometric tests that assess symptoms.
Psychosocial functioning is strongly correlated with
cognition and negative symptoms, but these domains are
currently poorly targeted by schizophrenia treatment. The
development of atypical antipsychotics was considered a
very important step in the treatment of schizophrenic
patients and a great hope at that moment also for
improving psychosocial functioning. Atypical
antipsychotics were created and proved to have less EPS
and sedation which could have made instrumental daily
activities easier; also improvement on negative symptoms
could have made the patient to regain interest and
initiative.
However, the results of later studies weren't so optimistic.
The latest data comparing typical and atypical
neuroleptics in schizophrenia treatment didn't reveal
important differences between the 2 classes of
antipsychotics regarding efficacy in improving cognitive
and negative symptoms (9, 13).
Clinical trials mostly assess efficacy (reduction of
symptoms), which is less easy extrapolated to real life. In
order to clearly define benefits of antipsychotics in
treatment of schizophrenia, a study should assess
effectiveness or achievement of functional outcomes,
since this could make the study more real-life oriented.
There are still scarce data on effectiveness of
schizophrenia treatments.
46
52 (46%) men.
GAF scale was applied by clinicians at baseline, 1, 2, 3, 6,
9, and 12 month (end of study).
Of the 113 patients in Romanian cohort of EUFEST study,
2 patients did not have valid baseline data and 20 patients
did not complete the study. We analysed sociodemographical and clinical characteristics differences
between completers and non-completers, because people
who didn't finish the study might be different (and
therefore could reduce the reliability of results) from
people who completed the study. We found that noncompleters were more frequently (significantly statistic)
having an occupation and reported a better Quality of Life
(significantly statistic) comparing with completers,
without any other differences. Data are presented in table
1.
Agea
Education (in
years) a
Genderb
Married (yes) b
Having an
occupation (yes) b
Composite
cognitive score
baselinea
Functionality
(GAF baseline) a
Quality of Life
(MANSA
baseline) a
PANSS total score
(baseline) a
PANSS positive
subscale
(baseline) a
PANSS negative
subscale
(baseline) a
PANSS general
psychopathology
subscale
(baseline) a
Depression
(CDSS, baseline) a
Complet
ers
27.12
(+/-6.11)
12.33(+/2.68)
52.7%
women
21.5%
48.4%
Noncompleters
25.91 (+/5.86)
12.95 (+/3.00)
60.0%
women
15.0%
75.0%
pvalue
.419
-.02 (+/.51)
.08 (+/-39)
.463
39.83
(+/12.87)
3.90 (+/.99)
34.37 (+/12.35)
.093
4.65 (+/.80)
.002
90.25
(+/19.71)
25.28
(+/-6.02)
88.65 (+/9.82)
.725
24.95 (+/5.89)
.822
20.50
(+/-7.50)
20.40 (+/6.44)
.956
44.47
(+/10.71)
43.30 (+/6.09)
.639
5.02 (+/5.83)
3.21 (+/4.14)
.201
.363
.626
.760
.047
Statistic = t-test
Statistic= chi-square test
Valentin P. Matei, Alexandra Mihailescu, Traian Purnichi, Ruxandra M. Al-bataineh: Antipsychotic Treatment And
Psychosocial Functioning In Schizophrenia Results From Romanian Cohort Of Eufest Study
in the population analysed in this study revealed no
baseline differences (Table 2a and 2b).
Age?
Gender?
Wo
men
Men
Haloperidol
Marital
status?
Mar Not
ried mar
ried
2
16
11.1 88.9
5
22
18.5 81.5
4
14
22.2 77.8
N
18
7
11
Mean 25.65 38.9 61.1
SD
5.98
Olanzapine
N
27
15
12
Mean 26.86 55.6 44.4
SD
6.19
Quetiapine
N
18
8
10
Mean 27.02 44.4 55.6
SD
6.13
Amilsulprid N
26
13
13
4
22
e
Mean 26.92 50.0 50.0
15.4 84.6
SD
5.42
Ziprasidone
N
24
18
6
8
16
Mean 27.8
75.0 25.0
33.3 66.7
SD
6.86
Analysis
Statis F=.31
2=.717
2=39.726
tic
7
dF
4
1
1
1
p
.866
.397 .000
.000
a
No significant differences between the 5 groups (ANOVA F,
p>0.05)
b
Percentage calculated based on the total sample at baseline
c
No significant differences between the 5 groups (2, p>0.05)
d
Significant differences between the 5 groups (2, p<0.05)
Halop
eridol
Olanz
apine
Quetia
pine
Amisu
lpride
Zipras
idone
P-values
between
classesa
Baselin
e
39.06
(+/13.56)
40.67
(+/12.71)
37.65
(+/17.05)
38.24
(+/12.52)
38.33
(+/10.26)
.943
Month
1
48.83
(+/16.29)
56.30
(+/16.73)
52.12
(+/13.33)
57.25
(+/15.25)
53.41
(+/11.78)
.322
Month
2
64.65
(+/8.94)
66.27
(+/14.40)
66.59
(+/11.55)
70.12
(+/14.73)
61.14
(+/13.62)
.241
Month
3
73.47
(+/8.88)
69.42
(+/13.41)
70.88
(+/11.60)
73.79
(+/13.17)
65.05
(+/14.82)
.184
Month
6
Month
9
73.48
(+/13.56)
74.24
(+/16.79)
74.00
(+/12.30)
75.62
(+/11.46)
78.65
(+/12.16)
77.76
(+/14.26)
68.58
(+/13.29)
75.39
(+/13.67)
.051
Educ
ation
(years
79.93
(+/9.64)
77.13
(+/13.16)
76.88
(+/16.20)
75.58
(+/18.41)
78.57
(+/10.15)
82.35
(+/10.16)
76.11
(+/9.47)
.533
)?
Haloperidol
PANSS
total
Current
occupation
scores?
?
No
10
55.6
Yes
8
44.4
N
18
18
Mean 11.94 91.61
SD
1.73
20.086
Olanzapine
N
27
27
12
15
Mean 12.52 88.48
44.4 55.6
SD
3.58
15.438
Quetiapine
N
18
17
10
8
Mean 12.61 98.82
55.6 44.4
SD
2.03
26.330
Amilsulprid N
26
26
9
17
e
Mean 12.42 86.85
34.6 65.4
SD
2.84
14.488
Ziprasidone
N
24
24
12
12
Mean 12.63 87.50
50.0 50.0
SD
2.67
16.133
Analysis
Statis F=.19 F=1.39
2=.434
tic
2
2
dF
4
4
1
p
.942
.242
.510
a
No significant differences between the 5 groups (ANOVA F,
p>0.05)
b
Percentage calculated based on the total sample at baseline
c
No significant differences between the 5 groups (2, p>0.05)
d
Significant differences between the 5 groups (2, p<0.05)
Month
12
.758
Treatment
arm
Sig.
(2tailed
)
Meana
SD
-9.778
11.715 -3.541
17 .003
Baseline to 2 months
16 .000
Baseline to 3 months
14 .000
Baseline to 6 months
14 .000
Baseline to 9 months
14 .000
16 .000
Study period
df
26 .000
Baseline to 2 months
25 .000
Baseline to 3 months
23 .000
Baseline to 6 months
Baseline to 9 months
22 .000
20 .000
23 .000
16 .001
Baseline to 2 months
15 .000
Baseline to 3 months
14 .000
Baseline to 6 months
11 .001
11 .000
12 .000
23 .000
Baseline to 2 months
22 .000
Baseline to 3 months
Baseline to 6 months
Baseline to 9 months
20 .000
21 .000
Baseline to 3 months
20 .000
Baseline to 6 months
Baseline to 9 months
18 .000
17 .000
49
Valentin P. Matei, Alexandra Mihailescu, Traian Purnichi, Ruxandra M. Al-bataineh: Antipsychotic Treatment And
Psychosocial Functioning In Schizophrenia Results From Romanian Cohort Of Eufest Study
REFERENCES
1.Riga S, Riga D, Mihailescu A, et al. Longevity health sciences and
mental health as future medicine. Ann NY Acad Sci. 2010;1197:184-7.
2.Living-Well-with-Chronic-Illness. (2011). Retrieved 2014, from
w w w. i o m . e d u : h t t p : / / w w w. i o m . e d u / ~ / m e d i a / F i l e s /
R e p o r t % 2 0 F i l e s / 2 0 1 2 / L i v i n g - We l l - w i t h - C h r o n i c Illness/livingwell_chronicillness_reportbrief.pdf
3.Twamley EW, Doshi RR, Nayak GV et al. Generalized cognitive
impairments, ability to perform everyday tasks, and level of
independence in community living situations of older patients with
psychosis. Am J Psychiatry 2002;159(12):2013-2020.
4.Swartz MS, Perkins DO, Stroup TS et al. Effects of antipsychotic
medications on psychosocial functioning in patients with chronic
schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry
2007;164:428-436.
5.Tandberg M, Sundet K, Andreassen OA, Melle I, Ueland T.
Occupational functioning, symptoms and neurocognition in patients
with psychotic disorders: investigating subgroups based on social
security status. Soc Psychiatr Epidemiol 2013, 48: 863874.
6.National Institute for Health and Care Excellence. CG178 Psychosis
and schizophrenia in adults: treatment and management. 2014
7.Grnder G, Hippius H & Carlsson A. The 'atypicality' of
antipsychotics: a concept re-examined and re-defined. Nat Rev Drug
Discov 2009;8(3):197-202.
8.The Collaborative Working Group on Clinical Trial Evaluations.
Assessing the effects of atypical antipsychotics on negative symptoms. J
Clin Psychiatry 1998;59 Suppl 12:28-34.
9.Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical
antipsychotics in the treatment of schizophrenia: systematic overview
and meta-regression analysis. Br Medical J 2000;321(7273):1371-6.
10.Meltzer H, Kostakaglu E, Lee M. Response. Negative Symptoms
Redux-Letters to the Editor. Neuropsychopharmacology
2000;22(6):662664.
11.Miller R. Mechanisms of Action of Antipsychotic Drugs of Different
Classes, Refractoriness to Therapeutic Effects of Classical Neuroleptics,
and Individual Variation in Sensitivity to their Actions: PART I. Curr
Neuropharmacol. 2009;7(4):302-314.
12.Lieberman JA, Stroup TS. et al. Clinical Antipsychotic Trials
ofIntervention Effectiveness (CATIE) Investigators Effectiveness of
antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med
2005;22(353):1209-23.
13.Kahn R, Fleischhacker WW, et al. Effectiveness of antipsychotic
drugs in first-episode schizophrenia and schizophreniform disorder: an
open randomised clinical trial. Lancet 2008;371(9618):1085-1097.
14.Tran PV, Dellva MA, Tollefson GD, et al. Oral olanzapine versus oral
haloperidol in the maintenance treatment of schizophrenia and related
psychoses. Br J Psychiatry 1998;172:499505.
15.Fleischhacker WW & Kemmler, G. The clinical relevance of
p e r c e n t a g e i m p r o v e m e n t s o n t h e PA N S S s c o r e .
50
Neuropsychopharmacology 2007;32(11):24352436.
16.Leucht S, Davis JM & Engel RR. Defining response in
antipsychotic drug trials: recommendations for the use of scale-derived
cutoffs. Neuropsychopharmacology 2007;32(9): 1903-1910.
17.Stroup TS, McEvoy JP, Swartz MS. The National Institute of Mental
Health Clinical Antipsychotic Trials of Intervention Effectiveness
(CATIE) project: schizophrenia trial design and protocol development.l.
Schizophr Bul 2003;29:15-31.
18.Jones PB, Barnes TR, Davies L. Randomized controlled trial of the
effect on Quality of Life of second- vs first-generation antipsychotic
drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in
Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry
2006;63(10):10791087.
19.Bowie CR, Twamley EW, Anderson H et al. Self-assessment of
functional status in schizophrenia. J Psychiatr Res 2007;41(12):10121018.
20.Hummer M, Fleischhacker WW. Do phase III trials have clinical
value? J Clin Psychopharmacol 1999;19:391392.
21.Agius M, Davis A, Gilhooley M, Chapman S & Zaman R. What do
large scale studies of medication in schizophrenia add to our
management strategies? Psychiatria Danubina 2010;22(2):323328.
22.American Psychiatric Association. Diagnostic and Statistical Manual
of Mental Disorders (DSM-IV-TR). Washington, DC: American
Psychiatric Press. 2000:34
23.Aas IH. Guidelines for rating Global Assessment of Functioning
(GAF). Annals of General Psychiatry 2011;10:2.
24.Brissos S, Molodynsky A et al. The importance of measuring
psychosocial functioning in schizophrenia. Annals of Gen Psychiatry
2011;10:18.
25.Fleischhacker WW, Keet IPM, Kahn RS. The European First Episode
Schizophrenia Trial (EUFEST): Rationale and design of the trial.
Schizophrenia Res 2005;78:147 156.
26.Fett AK, Viechtbauer W, Dominguez MD, Penn DL, van Os J,
Krabbendam L. The relationship between neurocognition and social
cognition with functional outcomes in schizophrenia: a meta-analysis.
Neurosci Biobehav Rev 2011;35:573-588.
27.Milev P, Ho BC, Arndt S, Andreasen NC. Predictive Values of
Neurocognition and Negative Symptoms on Functional Outcome in
Schizophrenia: A Longitudinal First-Episode Study With 7-Year FollowUp. Am J Psychiatry 2005;162:495-506.
28.Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus
placebo for relapse prevention in schizophrenia: a systematic review and
meta-analysis. Lancet 2012;379(9831):20632071.
29.Swartz M, Perkins DO, Stroup TS et al. Special Section on
Implications of CATIE: What CATIE Found: Results From the
Schizophrenia Trial. Psychiatric Services 2008;59(5):500-506.
***
ORIGINAL ARTICLES
Introduction
Depression represents a major cause of morbidity and
mortality (1). The prevalence of depression is increasing
(2) and by 2012 it is reported to be among the first 10
diseases causing loss of years due to disability (3).
Depression is responsible for the greatest proportion of
burden associated with non-fatal health outcomes
accounting for approximately 10% total years lived with
disability(4), more than cardiovascular disorders (2.8%),
diabetes (3.0%), or chronic respiratory diseases (6.3%) (3).
Chronic somatic illnesses are the cause of significant
burden on individuals, families, societies and countries.
Chronic somatic diseases that are frequent in the age group
18-44 years old are cardiovascular disease (most frequent
hypertension reported frequencies between 1.4%(5) and
8.7% (6)), cancer (aprox 2% prevalence (7)), diabetes
1
MD, PhD; University of Medicine and Pharmacy Carol Davila, Bucharest, Department Medical Psychology; Hospital of PsychiatryProf dr Al.
Obregia, Bucharest
2
MD, PhD; University of Medicine and Pharmacy Carol Davila, Bucharest, Department Psychiatry; Hospital of PsychiatryProf dr Al. Obregia,
Bucharest, email valipmatei@yahoo.com,
3
MD, PhD; University of Medicine and Pharmacy Carol Davila, Bucharest, Department Medical Psychology;
4
MD; Hospital of PsychiatryProf dr Al. Obregia, Bucharest
5
MD; Hospital of PsychiatryProf dr Al. Obregia, Bucharest
Received March 10, 2016, Revised March 25, 2016, Accepted May 31, 2016
51
Alexandra I. Mihailescu; Valentin P. Matei; Liliana V. Diaconescu, Ruxandra Al-bataineh, Md, Traian Purnichi :
Depression In Young Adults With Chronic Somatic Illness An Analysis Of 1970 British Cohort Study
(50,51).
The original study focused on children health and has
successively expanded to examine physical, educational
and social development of these children. Individuals
participating in this cohort study were assessed at birth
with a 96.7% response rate and in ongoing follow-ups
using a multi-method, multi informant approach.
Participants were followed up at 5 (n = 13 135, in 1970),
10 (n = 14 875 in ), 16 (n = 11 622 in 1986), 26 (n= 9003, in
1996), 30 (n = 11 261 in 2000) and 34 (n=9656, in 2004)
years of age.
At 30 years, marked efforts were made to recruit difficultto-reach subjects (51). Data for the present paper are
drawn from 30 years wave(52).
Measure of depression. At age 30, data was collected on
the severity of depressive symptoms using The Malaise
Inventory. An overall Malaise score for a cohort member
is the sum across the individual variables, yielding a
minimum score of 0 and a maximum of 24. A score of 8 or
higher is a recommended cut-off for a depressive episode
(53).
Measure of hypertension and diabetes. Data about
somatic illnesses were obtained from patients. At age 30
people from cohort were asked:
Have you ever had or been told you had high blood
pressure?
Have you ever had diabetes?
They could respond with yes, no, don't know and
not answered. We excluded from the analysis the last 2
groups of responders.
Measure for socio-economic status. Data about social
class of people from cohort were used as proxy for socioeconomic status (ses). Social classes were defined as such:
Professional, Managerial-technical, Skilled nonmanual, Skilled manual, Partly skilled and
Unskilled.
Statistical analyses. We created 2 groups, the first one
comprised of people considered controls (overall Malaise
score less or equal 7), the second one assumed to have
depression (Malaise score of 8 or over). The data were
afterward analysed with descriptive function, chi-square
and logistic regression. All analyses were performed using
SPSS 16.
Results.
Descriptive data. From a total of 11211 people there are
860 people with hypertension (7.7%) and 109 people with
diabetes (1%). From a total of 11211 people 1409 (12.6%)
have depression, and from this, 193 have developed
hypertension (high blood pressure) and 27 have developed
also diabetes, as it is shown in the figure below.
N=17
N=183
N=10
N=22
53
Alexandra I. Mihailescu; Valentin P. Matei; Liliana V. Diaconescu, Ruxandra Al-bataineh, Md, Traian Purnichi :
Depression In Young Adults With Chronic Somatic Illness An Analysis Of 1970 British Cohort Study
statistics/incidence/age#heading-Four
8. Early Release of Selected Estimates Based on Data From the National
Health Interview Survey, JanuaryMarch 2014 [Internet]. Available
from: http:// www.cdc. gov/nchs/ data/nhis/ earlyrelease/
earlyrelease201409_14.pdf
9. Versteeg H, Hoogwegt MT, Hansen TB, Pedersen SS, Zwisler A-D,
Thygesen LC. Depression, not anxiety, is independently associated with
5-year hospitalizations and mortality in patients with ischemic heart
disease. J Psychosom Res. 2013; Dec;75(6):51825.
10. Kent LK, Shapiro PA. Depression and related psychological factors
in heart disease. Harv Rev Psychiatry. 2009;Jan;17(6):37788.
11. Scalco AZ, Scalco MZ, Azul JBS, Lotufo Neto F. Hypertension and
depression. Clin (Sao
Paulo, Brazil). 2005; Jun;60(3):24150.
12. Ali S, Stone MA, Peters JL, Davies MJ, Khunti K. The prevalence of
co-morbid depression in adults with Type 2 diabetes: a systematic review
and meta-analysis. Diabet Med. 2006; Dec;23(11):116573.
13. Barnard KD, Skinner TC, Peveler R. The prevalence of co-morbid
depression in adults with Type 1 diabetes: systematic literature review.
Diabet Med. 2006; Apr;23(4):4458.
14. Opolski M, Wilson I. Asthma and depression: a pragmatic review of
the literature and recommendations for future research. Clin Pract
Epidemiol Ment Health. 2005; Sep 27;1:18.
15. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B.
Depression, chronic diseases, and decrements in health: results from the
World Health Surveys. Lancet (London, England). 2007; Sep
8;370(9590):8518.
16. Egede LE. Major depression in individuals with chronic medical
disorders: prevalence, correlates and association with health resource
utilization, lost productivity and functional disability. Gen Hosp
Psychiatry. 2007; Jan;29(5):40916.
17. Sartorius N, Ustn TB, Lecrubier Y, Wittchen HU. Depression
comorbid with anxiety: results from the WHO study on psychological
disorders in primary health care. Br J Psychiatry Suppl. 1996;
Jun;(30):3843.
18. Egede LE, Ellis C. Diabetes and depression: Global perspectives.
Diabetes Res Clin Pract. 2010; Mar;87(3):30212.
19. Li C, Ford ES, Zhao G, Ahluwalia IB, Pearson WS, Mokdad AH.
Prevalence and correlates of undiagnosed depression among U.S. adults
with diabetes: the Behavioral Risk Factor Surveillance System, 2006.
Diabetes Res Clin Pract. 2009; Feb;83(2):26879.
20. Li C, Ford ES, Strine TW, Mokdad AH. Prevalence of depression
among U.S. adults with diabetes: findings from the 2006 behavioral risk
factor surveillance system. Diabetes Care. 2008; Jan;31(1):1057.
21. Asghar S, Hussain A, Ali SMK, Khan AKA, Magnusson A.
Prevalence of depression and diabetes: a population-based study from
rural Bangladesh. Diabet Med. 2007; Aug;24(8):8727.
22. Mier N, Bocanegra-Alonso A, Zhan D, Wang S, Stoltz SM, AcostaGonzalez RI, et al. Clinical depressive symptoms and diabetes in a
binational border population. J Am Board Fam Med. 2008;
Jan;21(3):22333.
23. Goldney RD, Phillips PJ, Fisher LJ, Wilson DH. Diabetes,
depression, and quality of life: a population study. Diabetes Care. 2004;
May;27(5):106670.
24. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence
of comorbid depression in adults with diabetes: a meta-analysis.
Diabetes Care. 2001; Jun;24(6):106978.
25. Sotiropoulos A, Papazafiropoulou A, Apostolou O, Kokolaki A,
Gikas A, Pappas S. Prevalence of depressive symptoms among non
insulin treated Greek type 2 diabetic subjects. BMC Res Notes. 2008;
Jan;1:101.
26. Guo J, Whittemore R, Jeon S, Grey M, Zhou Z-G, He G-P, et al.
Diabetes self-management, depressive symptoms, metabolic control and
satisfaction with quality of life over time in Chinese youth with type 1
diabetes. J Clin Nurs. 2015; May;24(9-10):125868.
27. Naughton MJ, Yi-Frazier JP, Morgan TM, Seid M, Lawrence JM,
Klingensmith GJ, et al. Longitudinal associations between sex, diabetes
self-care, and health-related quality of life among youth with type 1 or
type 2 diabetes mellitus. J Pediatr. 2014; Jun;164(6):137683.e1.
28. Katon W, Lin EHB, Kroenke K. The association of depression and
anxiety with medical symptom burden in patients with chronic medical
illness. Gen Hosp Psychiatry. 2007; Jan;29(2):14755.
29. Evans DL, Charney DS. Mood disorders and medical illness: a major
public health problem. Biol Psychiatry. 2003; Aug 1;54(3):17780.
30. Nol PH, Williams JW, Untzer J, Worchel J, Lee S, Cornell J, et al.
Depression and comorbid illness in elderly primary care patients: impact
on multiple domains of health status and well-being. 2004; Ann Fam
Med. Jan;2(6):55562.
31. Wells KB, Sherbourne CD. Functioning and utility for current health
of patients with depression or chronic medical conditions in managed,
p r i m a r y c a r e p r a c t i c e s . A rc h G e n P s y c h i a t r y . 1 9 9 9 ;
Oct;56(10):897904.
32. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor
for noncompliance with medical treatment: meta-analysis of the effects
of anxiety and depression on patient adherence. Arch Intern Med. 2000;
54
Jul 24;160(14):21017.
33. Lin EHB, Katon W, Von Korff M, Rutter C, Simon GE, Oliver M, et
al. Relationship of depression and diabetes self-care, medication
adherence, and preventive care. Diabetes Care. 2004;
Sep;27(9):215460.
34. Sullivan M, Simon G, Spertus J, Russo J. Depression-related costs in
heart failure care. Arch Intern Med. 2002; Sep 9;162(16):18606.
35. Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes:
impact of depressive symptoms on adherence, function, and costs. Arch
Intern Med. 2000; Nov 27;160(21):327885.
36. Untzer J, Patrick DL, Simon G, Grembowski D, Walker E, Rutter C,
et al. Depressive symptoms and the cost of health services in HMO
patients aged 65 years and older. A 4-year prospective study. JAMA.
1997; May 28;277(20):161823.
37. Na Y-M, Kim K-S, Lee K-U, Chae J-H, Kim J-H, Kim D-J, et al. The
relationship between depressive symptoms in outpatients with chronic
illness and health care costs. Yonsei Med J. 2007; Oct 31;48(5):78794.
38. Hunkeler EM, Spector WD, Fireman B, Rice DP, Weisner C.
Psychiatric symptoms, impaired function, and medical care costs in an
HMO setting. Gen Hosp Psychiatry. 2003; Jan;25(3):17884.
39. Lustman PJ, Anderson RJ, Freedland KE, de Groot M, Carney RM,
Clouse RE. Depression and poor glycemic control: a meta-analytic
review of the literature. Diabetes Care. 2000; Jul;23(7):93442.
40. Van Tilburg MA, McCaskill CC, Lane JD, Edwards CL, Bethel A,
Feinglos MN, et al. Depressed mood is a factor in glycemic control in
type 1 diabetes. Psychosom Med. 2001; Jan;63(4):5515.
41. de Groot M, Kushnick M, Doyle T, Merrill J, McGlynn M, Shubrook
J, et al. Depression Among Adults With Diabetes: Prevalence, Impact,
and Treatment Options. Diabetes Spectr. 2010; Jan 21;23(1):158.
42. Egede LE, Bishu KG, Walker RJ, Dismuke CE. Impact of diagnosed
depression on healthcare costs in adults with and without diabetes:
United States, 2004-2011. J Affect Disord. 2016; May;195:11926.
43. Chiaie RD, Iannucci G, Paroli M, Salviati M, Caredda M, Pasquini
M, et al. Symptomatic subsyndromal depression in hospitalized
hypertensive patients. J Affect Disord. 2011; Dec;135(1-3):16876.
44. Rubio-Guerra AF, Rodriguez-Lopez L, Vargas-Ayala G, HuertaRamirez S, Serna DC, Lozano-Nuevo JJ. Depression increases the risk
for uncontrolled hypertension. Exp Clin Cardiol. 2013; Jan;18(1):102.
45. Davidson K, Jonas BS, Dixon KE, Markovitz JH. Do depression
symptoms predict early hypertension incidence in young adults in the
CARDIA study? Coronary Artery Risk Development in Young Adults.
Arch Intern Med. 2000; May 22;160(10):1495500.
46. Lippi G, Montagnana M, Favaloro EJ, Franchini M. Mental
depression and cardiovascular disease: a multifaceted, bidirectional
association. Semin Thromb Hemost. 2009; Apr;35(3):32536.
47. Nemeroff CB, Goldschmidt-Clermont PJ. Heartache and heartbreak-the link between depression and cardiovascular disease. Nat Rev
Cardiol. 2012; Sep;9(9):52639.
48. Vyas A, Sambamoorthi U. Multimorbidity and depression treatment.
Gen Hosp Psychiatry. 2011; Jan;33(3):23845.
49. Filipci I, Popovi-Grle S, Marcinko D, Basi S, Hotujac L, Pavici
F, et al. Screening for depression disorders in patients with chronic
somatic illness. Coll Antropol. 2007; Mar;31(1):13943.
50. Butler N, Golding J, Howlett B. From Birth to Five: A Study of the
Health and Behaviour of a National Cohort. Oxford: Pergamon; 1985.
51. Bynner J, Butler N, Ferri E, Shepherd P, Smith K. The Design and
Conduct of the 19992000 Surveys of the National Child Development
Study and the 1970 British Birth Cohort Study.CLS Cohort Studies
Working Paper 1. [Internet]. London: Centre for Longitudinal Studies ,
I n s t i t u t e o f E d u c a t i o n . 2 0 0 2 . Av a i l a b l e f r o m :
http://www.cls.ioe.ac.uk/studies.asp?section=0001000200020005
52. UK Data Service Discover 1970 British Cohort Study: TwentyN i n e - Ye a r F o l l o w - U p , 1 9 9 9 - 2 0 0 0 [ I n t e r n e t ] .
http://dx.doi.org/10.5255/UKDA-SN-5558-2
53. Rutter M, Tizard J, Whitmore K. Education, health and behaviour.
London: Longman; 1970.
54. Goldstein BI, Carnethon MR, Matthews KA, McIntyre RS, Miller
GE, Raghuveer G, et al. Major Depressive Disorder and Bipolar
Disorder Predispose Youth to Accelerated Atherosclerosis and Early
Cardiovascular Disease: A Scientific Statement From the American
Heart Association. Circulation. 2015; Sep 8;132(10):96586.
55. Meng L, Chen D, Yang Y, Zheng Y, Hui R. Depression increases the
risk of hypertension incidence: a meta-analysis of prospective cohort
studies. J Hypertens. 2012; May;30(5):84251.
56. Li Z, Li Y, Chen L, Chen P, Hu Y. Prevalence of Depression in
Patients With Hypertension: A Systematic Review and Meta-Analysis.
Medicine (Baltimore). 2015; Aug;94(31):e1317.
57. Harpole LH, Williams JW, Olsen MK, Stechuchak KM, Oddone E,
Callahan CM, et al. Improving depression outcomes in older adults with
comorbid medical illness. Gen Hosp Psychiatry. 2004; Jan;27(1):412.
58. Matheson FI, Smith KLW, Fazli GS, Moineddin R, Dunn JR, Glazier
RH. Physical health and gender as risk factors for usage of services for
mental illness. J Epidemiol Community Health. 2014;
Oct;68(10):9718.
CLINICAL CASE
schizophrenic patient.
Conclusion.
The scope of this paper was to show the importance of
performing a differential diagnosis and a thorough workup however certain we are of the patient's initial
presentation. We also wanted to emphasize the need for
studies that present more effective treatments of resistant
psychosis with fewer adverse reactions. The etiology of
schizophrenia presents a tremendous challenge for both
researchers and physicians, the latent toxoplasmosis
infection observed in high prevalence among
schizophrenic patients representing only a small part of
what remains to be discovered. Ultimately we must draw
attention to the importance of a multidisciplinary
approach to every case encountered.
Key words: resistant schizophrenia, Toxoplasma gondii,
Cooley's anemia, complex hallucinations
BACKGROUND
Treatment resistant schizophrenia represents a
challenge for any psychiatrist, especially if the patient
presents other co-morbidities like Cooley's anemia and
latent toxoplasmosis infection and a long course of
evolution as is the case presented in this article. The issue
of performing a well-documented differential diagnosis
remains equally important to a chronic patient with a long
psychiatric history and an apparently solid diagnosis of
paranoid schizophrenia as it is in the case of an acute de
novo psychotic episode. Research over the past years has
shown a high prevalence of Toxoplasmosis infection in
patients with neuropsychiatric symptoms and disorders,
most prominently in paranoid schizophrenia and mood
disorders, with influences on the course, severity,
treatment approach and response. [17,18,19,20,21]
We present the case of a 44 year-old caucasian
male (V.B) with a known psychiatric history of paranoid
schizophrenia, admitted to Prof. Dr. Al. Obregia Clinical
Hospital of Psychiatry during the months of May-July
2015 (67 days of hospitalization) for: compound and
complex auditory and visual hallucinations, paranoid
delusions, hallucinatory behavior, psychotic anxiety and
sleep disturbances, symptoms which had intensified in the
several months preceding admission despite following
treatment with clozapine 300mg/day and flupenthixol
decanoate depot 20mg/21days.
PAST PSYCHIATRIC HISTORY
The patient was first diagnosed with
Resident in Psychiatry, IX ward Prof Al. Obregia Academic Psychiatric Hosp., Bucharest, alex.barbilian@gmail.com
MD, PhD, Prof of Psychiatry, IX ward Prof Al. Obregia Academic Psychiatric Hosp., Bucharest.
Received May 4, 2016, Revised May12, 2016, Accepted May 16, 2016
2
55
Alexandra Barbilian, Dan Prelipceanu: Resistant Psychosis In A Patient With Coexisting Beta-thalassemia And Lantent
Toxoplasmosis
was never employed and keeps a very close relationship
with his sister who is also his caregiver. The patient doesn't
use nicotine or alcohol and has no relevant family
psychiatric history. From his family medical history we
know that his father dyed from metastatic lung cancer.
He denies having any allergies, is myopic and his medical
history involved two right humeral fractures and one right
scapular fracture, treated surgically in 2014 which the
patient recounts occurred when I was practicing boxing
and when I jumped off a tableI was training and an
uninvestigated chronic anemia which was treated with
iron supplements.
PSYCHIATRIC EXAMINATION performed on
19.05.2015: The patient appears to be his stated age, his
overall appearance is slightly disheveled although dressed
appropriately, wearing a suit and eye glasses, with
adequate hygiene and grooming. He exhibits slight
distress and anxiousness, seems uneasy but is cooperative.
Motor activity appears to be in normal limits although he
displays generalized jitteriness and restlessness. His
speech lacks in spontaneity, is slow and halting, quiet,
anxious and presents a slight stutter. There aren't
significant abnormalities in his thought process, his
answers are appropriate, most of the times to the point, at
times circumstantial. The patient is very polite, almost
manneristically so. The patient's thought content is
pathological, marked by persecutory and grandiose
delusions These people I see are out to get me, they're in
combat with me, they won't let me live. I have been
chosen by them, I'm the only one they can communicate
with. Perceptual disturbances are the prominent
symptoms in this patient. He describes ego-dystonic
compound hallucinations, both auditory: voices of people,
many of them, men and women, which commentate his
actions, talk to him and are most of the times imperative;
and visual hallucinations which are well-formed,
complex, include numerous people, animals and objects
there are thousands of them, men and women, a whole
world They are constantly looking at me. He also
describes scenic hallucinations I see the other world, of
those who are gone, I see where they are, what they're
doing, I see people right in this room, they're looking at
us. He perceives the audiovisual hallucinations as being
constant during the day while also interacting with the
other world and the people in it in his dreams. The patient
relates that the hallucinations had always been there, he
admits to perceiving them during the past years, but that
only in the last few months the voices had become
imperative My father is dead, he had glaucoma. They
urge me to take out my eye, my left eye and give it to him to
eat. In the last couple of months I have started to do what
they're asking, I'm trying to find a way to take it out, I don't
want to do it, but they're making me. He describes his
mood as being anxious I'm frightened about what the
voices are saying and making me do. The quality of his
affect is congruent with his mood and thought content, he
exhibits moderate anxiety and a restricted range of
emotions, both facial expression and voice lack
spontaneity. In contrast to the patient's cognitive abilities
(a score of 28 on MMSE with abstract reasoning within
normal ranges and a well-developed vocabulary) he has a
low level of functioning, an inability to hold a job or even
day-to-day chores I can't concentrate enough, I hear them
and I see them, I would love to read novels, but I can't, they
56
Alexandra Barbilian, Dan Prelipceanu: Resistant Psychosis In A Patient With Coexisting Beta-thalassemia And Lantent
Toxoplasmosis
results show a 15x higher probability of a continuous
course of disease and a negative impact on treatment.(21)
Another confirmation of the importance the infection has
on the evolution of schizophrenia is that a successful
treatment approach to both co-existing morbidities was a
good response to treatment with valproic acid, which once
added to our patient's clozapine treatment was the only
measure that improved his evolution and allowed for a
discharge.
CONCLUSIONS
The scope of this article was to show the
importance of performing a differential diagnosis and a
thorough work-up however certain we are of the patient's
initial presentation. We also wanted to emphasize the need
for studies that present more effective treatments with less
adverse reactions of resistant psychosis. The etiology of
schizophrenia presents a tremendous challenge for both
researchers and physicians, the latent toxoplasmosis
infection observed in high prevalence among
schizophrenic patients representing only a small part of
what remains to be discovered. Ultimately we must draw
attention to the importance of a multidisciplinary
approach to every case encountered.
References
1.Lally J, Tully J, Robertson D, Stubbs B, Gaughran F, MacCabe JH.
Augmentation of clozapine with electroconvulsive therapy in treatment
resistant schizophrenia: A systematic review and meta-analysis.
Schizophr Res. 2016 Mar;171(1-3):215-24.
2.Vogiatzi MG, Macklin EA, Fung EB, Cheung AM, Vichinsky E,
Olivieri N et al. Bone disease in thalassemia: a frequent and still
unresolved problem. Miner Res. 2009 Mar;24(3):543-57.
3.Exarchou E, Politou C, Vretou E, Pasparakis D, Madessis G,
Caramerou A. et al. Fractures and epiphyseal deformities in betathalassemia. Clin Orthop Relat Res. 1984 Oct;(189):229-33.
4.Vogiatzi MG, Macklin EA, Fung EB, Vichinsky E, Olivieri N,
Kwiatkowski J et al. Prevalence of fractures among the Thalassemia
syndromes in North America. Bone. 2006 Apr;38(4):571-5.
5.Zink M, Knopf U, Henn FA, Thome J. Combination of clozapine and
amisulpride in treatment-resistant schizophrenia--case reports and
review of the literature. Pharmacopsychiatry. 2004 Jan;37(1):26-31.
6.Cook B, Hoogenboom G. Combined use of amisulpride and clozapine
for patients with treatment-resistant schizophrenia. Australas Psychiatry.
58
2004 Mar;12(1):74-6.
7.Srisurapanont M, Suttajit S, Maneeton N, Maneeton B. Efficacy and
safety of aripiprazole augmentation of clozapine in schizophrenia: a
systematic review and meta-analysis of randomized-controlled trials. J
Psychiatr Res. 2015 Mar;62:38-47.
8.Mossaheb N, Kaufmann RM. Role of aripiprazole in treatmentresistant schizophrenia. Neuropsychiatr Dis Treat. 2012;8:235-44.
9.Mossaheb N, Spindelegger C, Asenbaum S, Fischer P, Barnas C.
Favourable results in treatment-resistant schizophrenic patients under
combination of aripiprazole with clozapine. World J Biol Psychiatry.
2010 Mar;11(2 Pt 2):502-5.
10.Hosk L, Libiger J. Antiepileptic drugs in schizophrenia: a review.
Eur Psychiatry. 2002 Nov;17(7):371-8.
11.Moriigo A, Martin J, Gonzalez S, Mateo I. Treatment of resistant
schizophrenia with valproate and neuroleptic drugs. Hillside J Clin
Psychiatry. 1989;11(2):199-207.
12.Sopko MA, Caley CF. Chronic leukocytosis associated with
clozapine treatment.Clin Schizophr Relat Psychoses. 2010 Jul;4(2):1414.
13.Manford M, Andermann F. Complex visual hallucinations. Clinical
and neurobiological insights. Brain. 1998 Oct;121 ( Pt 10):1819-40.
14.Grover S, Hazari N, Chakrabarti S, Avasthi A. Association of
Clozapine with Seizures: A Brief Report Involving 222 Patients
Prescribed Clozapine. East Asian Arch Psychiatry. 2015 Jun;25(2):73-8.
15.Williams AM, Park SH. Seizure associated with clozapine: incidence,
etiology, and management. CNS Drugs. 2015 Feb;29(2):101-11.
16.Borras L, Huguelet P. Schizophrenia and beta-thalassemia: a genetic
link?Psychiatry Res. 2008 Mar 15;158(2):260-1.
17.Flegr, J. Influence of latent Toxoplasma infection on human
personality, physiology and morphology: pros and cons of the
Toxoplasma-human model in studying the manipulation hypothesis.J
Exp Biol. 2013 Jan 1;216(Pt 1):127-33.
18.Fond G, Capdevielle D, Macgregor A, Attal J, Larue A, Brittner M,
Ducasse D, Boulenger JP. [Toxoplasma gondii: a potential role in the
genesis of psychiatric disorders].[Article in French] Encephale. 2013
Feb;39(1):38-43.
19.Henriquez SA, Brett R, Alexander J, Pratt J, Roberts CW.
Neuropsychiatric disease and Toxoplasma gondii infection.
Neuroimmunomodulation. 2009;16(2):122-33.
20.Cevizci S, Celik M, Akcali A, Oyekcin DG, Sahin OO, Bakar C.
Seroprevalence of anti-Toxoplasma gondii and anti-Borrelia species
antibodies in patients with schizophrenia: a case-control study from
western Turkey. World J Biol Psychiatry. 2015 Jun;16(4):230-6.
21.Celik T, Kartalci S, Aytas O, Akarsu GA, Gozukara H, Unal S.
Association between latent toxoplasmosis and clinical course of
schizophrenia - continuous course of the disease is characteristic for
Toxoplasma gondii-infected patients.Folia Parasitol (Praha). 2015 Jan
1;62. pii: 2015.015.
***
Mihai Ardelean este medic primar psihiatru, dr. n medicin, liceniat n istorie al Facutii de Istorie a Universitii Babe - Bolyai' din Cluj Napoca i
lucreaz la Ambulatorul de Specialitate al Spitalului Judeean din Tg. Mure.
1
Bartos Zoltn (editor), Ministerul Afacerilor Interne/Ministerul Securitii Statului/Consiliul Securitii Statului, Direcia Regional Mure (19511952)/Direcia Regional Autonom Maghiar (1952-1960)/Direcia Regional Mure-Autonom Maghiar (1960-1968)/Inspectoratul de Securitate
al Judeului Mure (1968), Documente, Ed. Risoprint, Cluj-Napoca, 2012, p. 739-740.
2
Ibidem, p. 235
3
Ibidem.
4
Arhiva C.N.S.A.S., Dosar I. 259025, vol. 1, vol. 2.
Primit 4.04.2016, Revizuit 14.04.2016, Acceptat 22.04.2016
59
5
ntr-o alt not informativ, din 14 II 1963, se aduc lmuriri asupra electroocurilor ca metod de tratament: Sursa [Alexandru] v informeaz c
aa numitul tratament de abrazare sau n mod laic cum se spune de blegeal. Acest tratament este unul din tratamentele importante i majore care
se aplic la orice spital de neuropsihiatrie. Indicaiile la care se aplic acest tratament sunt bolile mintale care prezint turburri de comportament, de
conduit i turburri de caracter (cade ntr-o beie, reclamanii imorali etc.). (Arhiva C.N.S.A.S., Dosar I. 259025, vol. 1, f. 16.).
60
61
Ibidem,f. 14-15.
62
NOT INFORMATIV
9. 06. 1962
n ziua de 9 mai 1962, sursa a stat de vorb la
Svrin cu Dr. LOHAN TRAIAN, printre altele a discutat
despre viaa acestuia. Sursa l-a ntrebat ce a fcut n cei
cinci ani de la terminarea liceului pn la nscrierea n
facultate, iar LOHAN i-a spus c n cei cinci ani a fost de
toate. nti femeie de serviciu, infirmier, oficiant sanitar
i apoi tehnician radiolog, adic a fost ncadrat pe aceste
posturi.
ntrebat cum se mpac cu directorul Dr. DAN
ARTHUR, Dr. LOHAN a spus c este un om de treab i c
e pcat c e paralizat, fiind un om foarte capabil i un
excepional psiholog.
Apoi a povestit c la el acas nu a fost dect de
dou ori i nici nu ndrznete s mearg, s nu se cread c
merge pentru soia acestuia cu care este foarte bine.
Apoi, Dr. LOHAN a nceput s povesteasc ce a
pit o bolnav internat n secia lui, n legtur cu
calitatea lui de psiholog a dr.[lui] DAN. Aceast bolnav,
dup internare, a fost la cabinetul directorului pentru
examen psihologic i pentru ncheierea17 tratamentului, dr.
DAN, dup ce a vzut biletul de trimitere, i-a spus
bolnavei c ea sufer din motive amoroase, iar bolnava,
fcnd o scen de histerie, a nceput s plng, s se revolte
i, n cele din urm, s cear s i se fac ieirea din
sanatoriu. Dar dr. DAN foarte calm a linitit-o pe bolnav
i a rugat-o s se aeze pe scaun i s renceap s-i
vorbeasc despre boal. Bolnava ntr-adevr s-a linitit,
pn la urm a recunoscut c dr. DAN i-a descoperit
tainele suferinei ei. Aceasta a povestit bolnava n salon
Dr.[lui] LOHAN i la celelalte bolnave i era ncntat de
calitile acestui doctor (dr. Arthur Dan n.n.).
ntrebat de surs dac soia dr.[lui] DAN se cam
plimb, cci a vzut-o de cteva ori prin gar, Dr. LOHAN
a spus rznd c probabil i caut i ea vreun amant.
ss.Munteanu Gheorghe18
Cu aceti pai terapeutici efectuai de un mare psihiatru,
marcat de neputina de a pi cu adevrat, ncheiem
incursiunea noastr prin arhivele Securitii. Dan Arthur,
intuit fiind ntr-un fotoliu, aflat ns n centrul ateniei
pacienilor si, al colegilor-discipoli i al informatorilor
Securitii, a jucat rolul unui psihiatru formator. Un
formator direct pentru cei care s-au dus s nvee de la el, i
indirect pentru cei care au construit n jurul lui o legend a
practicrii unei psihiatrii eliberate de stringena
politicului. Reasamblarea documentelor din dosarele
CNSAS seamn cu ncercarea de a reconstitui
evenimente ca ntr-o docu-dram, necesar pentru a
nelege limbaje i comportamente dintr-o epoc dificil de
neles. Mai cu seam, dac inem seama c, aidoma
teatrului clasic, unitatea de loc i de aciune a fost pstrat
n cazul dosarului lui Dan Arthur, drama psihiatrului
paraplegic derulndu-se pe scena singular a celei mai
inedite instituii psihiatrice, din Romnia comunist,
Sanatoriul Republican de Nevroze de la Svrin.
12
Ibidem, f. 5.
Ibidem, f. 10.
14
Ibidem, f. 11.
15
Ibidem.
16
Ibidem, f. 37.
17
La redactare, ofierul de Securitate, nefiindu-i familiar sintagma medical iniierea tratamentului, a consemnat ncheierea tratamentului.
13
63
A submitted manuscript will be acknowledged and assigned a manuscript number, which is to be used in all further
correspondence. Manuscripts are reviewed and given a priority based on their originality, importance of the findings,
scientific merit and significance for the field, interest to readers, lucidity, and suitability for publication. Manuscripts with
insufficient priority for publication are rejected promptly. Other manuscripts are sent to expert consultants for peer review.
The existence of a manuscript under review is not revealed to anyone other than peer reviewers and editorial staff. Peer
reviewers remain anonymous and are expected to maintain strict confidentiality. After the review process has been
completed, authors will be informed by mail of the Editor's decision.
Corrections
Scientific fraud is rare events; however, they have a very serious impact on the integrity of the scientific
community. If the Editorial Board uncovers possible evidence of such problems it will first contact the corresponding author
in complete confidence, to allow adequate clarification of the situation. If the results of such interactions are not satisfactory,
the Board will contact the appropriate official(s) in the institution(s) from which the manuscript originated. It is then left to
the institution(s) in question to pursue the matter appropriately. Depending on the circumstances, the Romanian Journal of
Psychiatry may also opt to publish errata, corrigenda, or retractions.
Manuscript Preparation
Romanian authors should send both the Romanian and English version of the article, including title, abstract and
key words. Foreign authors should send the English version of the article.
Manuscripts must be prepared in conformity to the Uniform Requirements for Manuscripts Submitted to
Biomedical Journals: Writing and Editing for Biomedical Publication issued by the International Committee of Medical
Journal Editors (www.icmje.org).
Articles must be written in Microsoft Word, Style: Normal + Justify, Font: Times New Roman, size 12. All
manuscripts must be typed double-spaced. Original source files, not PDF files, are required. In text editing, authors should
not use spacing with spacebar, tab or paragraph mark, but use the indentation and spacing options in Format -> Paragraph.
Automatic paging is preferred.
Subheadings of the article should be left-justified, typed with capital letters, Font: Times New Roman, size 12.
The abstracts and Key words must be written in Microsoft Word, Style: Normal + Justify, Font: Times New Roman,
size 11, italics.
Figures must be cited in order in the text using Arabic numerals, (e.g., fig.2). Their width should be 6,5cm (in order
to fit in a column) or 13,5 cm (in order to fit in both columns). The figures have to satisfy the following conditions:
- black and white photographs with good contrast, with recommended sizes;
- scanned photograph with a resolution of 300 dpi and subsequently edited on a computer, original file (*TIF,
*JPG);
- illustrations (drawings, charts) created on a computer, cited in the text, original file (*XLS, *CDR).
Every figure should be accompanied by a title and a legend.
Tables, numbered consecutively with arabic numerals, should have a width of 6,5 cm or 13,5 cm. Every table
should be also accompanied by a title and a legend. The distribution of tables and figures in the text should be balanced.
Please do not import tables or figures into the text document, but only specify their insertion in text (e.g., Table No.3
insertion). They have to be sent in separate files. Files should be labeled with appropriate and descriptive file names.
Manuscript organization
1. First page should include:
Article title: titles should be short, specific, and descriptive, emphasizing the main point of the article. Avoid a 2part title, if at all possible. Do not number the title, e.g., I or Part I. Do not make a declarative statement in the title. Title
length, including punctuation and spaces, ideally should be under 100 characters and must not exceed 150 characters.
2. Second page:
a) Author(s). First name, middle initials and surname of the authors, without any scientific, didactic or
military degrees; (e.g., Mircea A Bir, Aura Vaida, not Bir M.A., Vaida A.).
b) Footnote that specifies the authors' scientific titles, the name and the address of their workplaces
(institution and department) for each author; contact details of the corresponding author (full address,
telephone number, fax number, e-mail address) and the address of the institution and department where
the study has been carried out. Contact details will be published unless otherwise requested by the author.
3. Third page:
a) Abstracts should have no more than 300 words. For original articles they should consist of five
paragraphs, labeled Background, Objective(s), Method(s), Result(s), and Conclusion(s).
b) Keywords maximum of 6 keywords (minimum of 3), according to Index medicus. Keywords should not
repeat the title of the manuscript.
4. Fourth page and next:
Original papers organized in:
a) Introduction (no more than 25% of the text), material and methods, results, comments or discussions and
65
acknowledgements.
b) Material and methods have to be described in enough detail to permit reproduction by other teams. The
same product names should be used throughout the text (with the brand name in parenthesis at the first
use).
c) Results should be presented concisely. Tables and figures should not duplicate text.
d) The discussions should set the results in context and set forth the major conclusions of the authors.
Information from the Introduction or Results should not be repeated unless necessary for clarity. The
discussion should also include a comparison among the obtained results and other studies from the
literature, with explanations or hypothesis on the observed differences, comments on the importance of
the study and the actual status of the investigated subject, unsolved problems, questions to be answered
in the future.
e) In addition to the customary recognition of non-authors who have been helpful to the work described, the
acknowledgements section must disclose any substantive conflicts of interest.
f) Abbreviations shall be preceded by the full term at their first apparition in text. A list of all used
abbreviations shall be made at the end of the article.
g) Separate pages: tables, graphics, pictures and schemes will appear on separate pages.
References should be numbered consecutively in the order in which they are first mentioned in the text. Identify
references in text, tables, and legends by Arabic numerals in parentheses.
The reference list will include only the references cited in the text (identified by Arabic numerals in
parentheses, not in square brackets and not bold).
All authors should be listed when six or less; when seven or more, list only the first three and add 'et al'
(Ionescu I, Popescu I, Georegscu I et al).
The name of the Journals cited in the References should be abbreviated according to ISI Journal Title
Abbreviations.
Examples:
- Reference to a journal publication:
Vrati R, Matei VMI. The crisis centre in Romania. Eur J Psychiat 2002; 29:305-311.
Reynolds CF, Frank E, Perel JM et al. Treatment of consecutive episodes of major depression in the elderly. Am J
Psychiat 1994; 151(12):1740-3.
- Reference to a book:
Vrasti R. The crisis centre in psychiatry. Toronto, London: Academic Press, 1993, 26-52.
- Reference to a chapter in an edited book:
Schuckit MA. Alcohol-Related Disorders. In: Sadock BJ, Sadock VA, Ruiz P (eds). Comprehensive Textbook of
Psychiatry. Philadelphia: Lippincott Williams and Wilkins, 2009, 1268-1287.
The placement of the italics, punctuation and the general aspect of the text format must comply with the rules
mentioned above. This is a mandatory and eliminatory condition.
INSTRUCTIONS FOR MANUSCRIPTS SUBMITTED IN ELECTRONIC FORMAT
The text should be edited in Word for Windows.
1. Use as few formatting commands as possible:
- input your text continuously (without breaks);
- do not use different types of fonts to highlight your text;
- any word or phrase that you would like to emphasize should be indicated throughout the text by underlining;
- use only the Enter key to indicate the end of the end of paragraphs, headings, lists etc.;
- do not use the Space Bar to indicate paragraphs, but only the Tab key.
2. Charts and tables should be edited in Word or Excel. Please indicate in the text, the place of the table, specifying
its name.
3. You can scan photographs (using Photostyler, Adobe-Photoshop or any other compatible programs) and save
them as .tif or .jpg files. Please indicate in the text, the place of the photograph, specifying its name.
4. You may use a common compression program: ARJ, RAR or ZIP.
5. Make sure that the text file from CD and the print-out correspond exactly.
6. Make sure that there are no errors on your CD.
7. Make sure your CD is adequately packed.
8. Make sure your CD has no viruses.
VERY IMPORTANT: All manuscripts intended for publication will be subject to peer-review by a committee of
experts which assesses the scientific and statistical correctness of articles submitted. The committee receives the
manuscripts without knowing the authors' name and proposes possible changes, which will be transmitted to the authors by
the medium of Editorial Board. The authors have the obligation to oversee the text in English language with the help of a
professional translator.
66
67
ROMANIAN JOURNAL
OF PSYCHIATRY
CONTENTS
EDITOR-IN-CHIEF:
CO-EDITORS:
SPECIAL ARTICLES
& Depression and Suicide in Women Characters of The Early 20th
Century
Ionu I. Jeican, Doina C.M. Cozman
29
REVIEW ARTICLES
&
34
&
&
39
45
51
CLINICAL CASE
&
55
59
64
Romanian Journal of Psychiatry and Psychotherapy is indexed in the international data base Index
Copernicus Journal Master List, starting with 2009.
APR
ASSOCIATE EDITORS:
Doina COZMAN
Liana DEHELEAN
Marieta GABO GRECU
Maria LADEA
Cristinel TEFNESCU
Ctlina TUDOSE
Executive editors: Elena CLINESCU
Valentin MATEI
ORIGINAL ARTICLES
&
Dan PRELIPCEANU
Drago MARINESCU
Aurel NIRETEAN
STEERING COMMITTEE:
Vasile CHIRI (Honorary Member
of the Romanian Academy of
Medical Sciences, Iai)
Michael DAVIDSON (Professor, Sackler
School of Medicine Tel Aviv Univ.,
Mount Sinai School of Medicine,
New York)
Virgil ENTESCU (Member of the Romanian
Academy of Medical Sciences, Satu
Mare)
Ioana MICLUIA (UMF Cluj-Napoca)
erban IONESCU (Paris VIII Universiy, TroisRivieres University, Quebec)
Mircea LZRESCU (Honorary Member of the
Romanian Academy
of Medical Sciences, Timioara)
Juan E. MEZZICH (Professor of Psychiatry
and Director, Division of Psychiatric
Epidemiology and International
Center for Mental Health, Mount
Sinai School of Medicine, New York
University)
Teodor T. POSTOLACHE, MD (Director,
Mood and Anxiety Program,
Department of Psychiatry,
University of Maryland School of
Medicine, Baltimore)
Sorin RIGA (senior researcher)
Dan RUJESCU (Head of Psychiatric Genomics
and Neurobiology
and of Division of Molecular and
Clinical Neurobiology,
Department of Psychiatry, LudwigMaximilians-University, Munchen)
Eliot SOREL (George Washington University,
Washington DC)
Maria GRIGOROIU-ERBNESCU
(senior researcher)
Tudor UDRITOIU (UMF Craiova)
www.romjpsychiat.ro